Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Placebo Group

Core clinician-reference fields are available or not applicable.

Participants received a multi-strain probiotic formula alongside standard hypoglycemic therapy.

Probiotic Group

Participants in the probiotic group consumed one strip of the probiotic formulation daily for 12 weeks, in addition to standard hypoglycemic therapy.

Participants received a matched placebo strip containing only dextrin.

Participants in the placebo group received one matched strip per day containing only dextrin, identical in appearance, weight, color, and packaging to the probiotic product.

Authoritative quality diagnostic: p value significance conflict.

Probiotic improves metabolic profiles in type 2 diabetes patients

Participants received a multi-strain probiotic supplement daily for 6 months.

A total of 91 adults with T2D (mean age [±SD] 65.12 ± 10.92 years, 62.6% males) were randomized to receive the probiotic supplement (n = 46) compared to the controls (n = 45).

Participants received a matching placebo capsule daily for 6 months.

Participants were randomized to receive the probiotic supplement or a matching placebo capsule, both taken once daily.

Probiotic Supplementation Improves Glycemic Control in Type 2 Diabetes

Available source content was suppressed because validation identified a conflict.

Participants received a multi-strain probiotic alongside metformin treatment.

They were randomised 1:1 to receive either a multi-strain probiotic (2 × 10^9 CFU/day) or placebo.

Participants received a placebo alongside metformin treatment.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Probiotics reduce GI side effects of metformin without improving metabolic efficacy

Placebo capsule

Participants received one capsule of multi-species probiotic plus 100 mg fructo-oligosaccharide supplement daily for 8 weeks.

Daily synbiotic supplement

In this randomized double-blind placebo controlled clinical trial, 50 patients suffering from T2DM and periodontal disease were recruited and randomly assigned to two groups: intervention group (n = 25), where one capsule of multi-species probiotic plus 100 mg fructo-oligosaccharide supplement (500 mg in each capsule) every day is given.

Participants received one placebo capsule containing 500 mg wheat flour daily for 8 weeks.

and control group (n = 25), which received one placebo capsule containing 500 mg wheat flour for 8 weeks.

Synbiotic supplementation improves glycemic control in type 2 diabetes patients.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 2 studies described adult participants.

1 of 2 studies with duration data have follow-up of 12 weeks or less.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 1 study described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved, usual_care.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: other, usual_care.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Evidence uses heterogeneous comparison contexts: placebo, unknown_unresolved, usual_care.

Structured population data were available for 6 of 6 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

3 of 6 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.

4 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.

2 studies contain conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Structured population data were available for 9 of 9 supporting studies. Diabetes type was heterogeneous: 4 studies with type 1 diabetes, 2 studies with type 2 diabetes. 7 studies described adult participants.

Multi-species synbiotic (12 probiotic strains + FOS prebiotic) × Fasting Plasma Glucose (FPG)

Available supporting studies

Probiotic improves metabolic profiles in type 2 diabetes patients

Probiotic Supplementation Improves Glycemic Control in Type 2 Diabetes

Probiotics reduce GI side effects of metformin without improving metabolic efficacy

Synbiotic supplementation improves glycemic control in type 2 diabetes patients.